Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
Novartis’ Phase 3 HORIZON trial for pelacarsen failed to reduce cardiovascular events in the overall study population, Royalty Pharma said Friday. The result removes a major potential royalty-growth catalyst for RPRX, although the filing’s full financial impact and any subgroup findings remain to be established.
What happened
Novartis’ Phase 3 HORIZON trial for pelacarsen failed to reduce cardiovascular events in the overall study population, Royalty Pharma said Friday.
The read · Sep 4
The failed HORIZON endpoint moves the near-term risk to the downside for RPRX by weakening the outlook for a potential pelacarsen royalty stream.
Wrong if
The trade read is weakened if the full HORIZON dataset shows a clinically meaningful prespecified subgroup, or if Royalty Pharma discloses that pelacarsen has little effect on expected royalty cash flows.
CoverageFirst reported by GlobeNewswire at 7:05 PM ET · the only report so farHow this is decided →
The chart · RPRXTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
Royalty Pharma said Sept. 4 that Novartis’ Phase 3 HORIZON outcomes trial for pelacarsen did not meet its primary endpoint. The study tested whether the antisense oligonucleotide could reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and elevated lipoprotein(a), or Lp(a). The endpoint combined cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and urgent coronary revascularization requiring hospitalization.
The result is a setback for a program aimed at a genetically defined cardiovascular-risk population. HORIZON was designed to test the clinical-outcomes benefit of lowering Lp(a), rather than merely demonstrating a change in the biomarker. The announcement provides the topline result but does not, in the supplied material, give the size of the treatment effect, the statistical details, or a decision on the program’s next step.
The principal corporate link is between Novartis, the developer of pelacarsen, and Royalty Pharma, which has an economic interest in approved or commercialized medicines through royalty arrangements. A failed primary endpoint can reduce the probability that a program reaches commercialization or generates the expected royalty stream. RPRX’s enrichment shows fiscal-2025 revenue of $2.4B, up 5.1% year over year, with diluted EPS of $1.78 and a 32.4% net margin; the release does not quantify pelacarsen’s contribution to those figures.
The topline announcement is not a complete readout of the trial. The supplied report does not say whether a subgroup met the endpoint, whether safety findings changed the risk profile, or whether Novartis plans additional analysis or development. It also does not establish the accounting treatment or timing of any effect on Royalty Pharma’s reported revenue.
The next useful disclosures are the full HORIZON data, including the hazard ratio, confidence interval, statistical significance, subgroup results and safety profile. Investors will also need Novartis’ stated development decision and Royalty Pharma’s next filing or earnings commentary to determine how the result affects expected cash flows. Until those details arrive, the size of the royalty setback cannot be pinned down from the topline statement alone.
The read, in fullWhy it matters
The immediate issue is cash-flow optionality: a failed primary endpoint lowers the probability that pelacarsen becomes a meaningful royalty asset, while RPRX’s supplied figures do not identify how much of its $2.4B revenue base depends on the program. The read is negative, but the missing treatment-effect, subgroup and accounting details prevent a quantified single-name call until Novartis and Royalty Pharma provide a fuller update.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written
Next · what would move this
Into the full HORIZON readout and next RPRX update. Follow to be told when one lands.
▲ The case it holds
The strongest bull case is that a prespecified subgroup or favorable full safety and efficacy profile preserves a development path despite the missed overall endpoint, while RPRX’s $2.4B revenue base limits the disclosed exposure.
▼ The case it breaks
The bear case is that failure on the composite cardiovascular-event endpoint materially reduces pelacarsen’s commercialization probability and removes a potential growth catalyst from RPRX’s royalty portfolio.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →